V 1 /V 2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction

Norberto Perico, Carla Zoja, Daniela Corna, Daniela Rottoli, Flavio Gaspari, Lloyd Haskell, Giuseppe Remuzzi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Blockade of the renin-angiotensin system (RAS), the standard treatment for chronic proteinuric nephropathy, slows but may not halt progression of the disease, particularly when therapy is started late. Because vasopressin may also play a role in the progression of renal disease, we measured the effect of a dual V 1a and V 2 vasopressin receptor antagonist (RWJ-676070) alone or combined with angiotensin-converting enzyme inhibition or angiotensin II type 1 receptor blockade on proteinuria and renal disease progression during overt nephropathy. Twenty-one days after renal mass reduction, a time of established injury, rats were given vehicle, RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril, or losartan in drinking water for an additional 39 days. RWJ-676070 returned the blood pressure to pre-treatment levels, which were significantly lower than those in vehicle-treated rats. Enalapril, losartan, and the combined therapies reduced blood pressure to a greater extent. RWJ-676070 afforded a partial antiproteinuric effect, which was enhanced by the addition of enalapril or losartan. Renal functional impairment, and glomerular and tubular changes were partially ameliorated by RWJ-676070; parameters significantly improved with either enalapril or losartan alone and improved to a greater extent with the combined therapies. Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy.

Original languageEnglish
Pages (from-to)960-967
Number of pages8
JournalKidney International
Volume76
Issue number9
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Vasopressin Receptors
Renin-Angiotensin System
Enalapril
Losartan
Kidney
Disease Progression
Blood Pressure
Angiotensin Type 1 Receptor
Peptidyl-Dipeptidase A
Therapeutics
Vasopressins
Proteinuria
Drinking Water
RWJ-676070
Wounds and Injuries

Keywords

  • ACE inhibitor
  • Angiotensin receptor blocker
  • Proteinuric nephropathy
  • Renal injury
  • Renal mass reduction
  • Vasopressin receptor antagonist

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{9448dea561134e0082ebe1fccd6c86f0,
title = "V 1 /V 2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction",
abstract = "Blockade of the renin-angiotensin system (RAS), the standard treatment for chronic proteinuric nephropathy, slows but may not halt progression of the disease, particularly when therapy is started late. Because vasopressin may also play a role in the progression of renal disease, we measured the effect of a dual V 1a and V 2 vasopressin receptor antagonist (RWJ-676070) alone or combined with angiotensin-converting enzyme inhibition or angiotensin II type 1 receptor blockade on proteinuria and renal disease progression during overt nephropathy. Twenty-one days after renal mass reduction, a time of established injury, rats were given vehicle, RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril, or losartan in drinking water for an additional 39 days. RWJ-676070 returned the blood pressure to pre-treatment levels, which were significantly lower than those in vehicle-treated rats. Enalapril, losartan, and the combined therapies reduced blood pressure to a greater extent. RWJ-676070 afforded a partial antiproteinuric effect, which was enhanced by the addition of enalapril or losartan. Renal functional impairment, and glomerular and tubular changes were partially ameliorated by RWJ-676070; parameters significantly improved with either enalapril or losartan alone and improved to a greater extent with the combined therapies. Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy.",
keywords = "ACE inhibitor, Angiotensin receptor blocker, Proteinuric nephropathy, Renal injury, Renal mass reduction, Vasopressin receptor antagonist",
author = "Norberto Perico and Carla Zoja and Daniela Corna and Daniela Rottoli and Flavio Gaspari and Lloyd Haskell and Giuseppe Remuzzi",
year = "2009",
month = "11",
doi = "10.1038/ki.2009.267",
language = "English",
volume = "76",
pages = "960--967",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - V 1 /V 2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction

AU - Perico, Norberto

AU - Zoja, Carla

AU - Corna, Daniela

AU - Rottoli, Daniela

AU - Gaspari, Flavio

AU - Haskell, Lloyd

AU - Remuzzi, Giuseppe

PY - 2009/11

Y1 - 2009/11

N2 - Blockade of the renin-angiotensin system (RAS), the standard treatment for chronic proteinuric nephropathy, slows but may not halt progression of the disease, particularly when therapy is started late. Because vasopressin may also play a role in the progression of renal disease, we measured the effect of a dual V 1a and V 2 vasopressin receptor antagonist (RWJ-676070) alone or combined with angiotensin-converting enzyme inhibition or angiotensin II type 1 receptor blockade on proteinuria and renal disease progression during overt nephropathy. Twenty-one days after renal mass reduction, a time of established injury, rats were given vehicle, RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril, or losartan in drinking water for an additional 39 days. RWJ-676070 returned the blood pressure to pre-treatment levels, which were significantly lower than those in vehicle-treated rats. Enalapril, losartan, and the combined therapies reduced blood pressure to a greater extent. RWJ-676070 afforded a partial antiproteinuric effect, which was enhanced by the addition of enalapril or losartan. Renal functional impairment, and glomerular and tubular changes were partially ameliorated by RWJ-676070; parameters significantly improved with either enalapril or losartan alone and improved to a greater extent with the combined therapies. Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy.

AB - Blockade of the renin-angiotensin system (RAS), the standard treatment for chronic proteinuric nephropathy, slows but may not halt progression of the disease, particularly when therapy is started late. Because vasopressin may also play a role in the progression of renal disease, we measured the effect of a dual V 1a and V 2 vasopressin receptor antagonist (RWJ-676070) alone or combined with angiotensin-converting enzyme inhibition or angiotensin II type 1 receptor blockade on proteinuria and renal disease progression during overt nephropathy. Twenty-one days after renal mass reduction, a time of established injury, rats were given vehicle, RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril, or losartan in drinking water for an additional 39 days. RWJ-676070 returned the blood pressure to pre-treatment levels, which were significantly lower than those in vehicle-treated rats. Enalapril, losartan, and the combined therapies reduced blood pressure to a greater extent. RWJ-676070 afforded a partial antiproteinuric effect, which was enhanced by the addition of enalapril or losartan. Renal functional impairment, and glomerular and tubular changes were partially ameliorated by RWJ-676070; parameters significantly improved with either enalapril or losartan alone and improved to a greater extent with the combined therapies. Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy.

KW - ACE inhibitor

KW - Angiotensin receptor blocker

KW - Proteinuric nephropathy

KW - Renal injury

KW - Renal mass reduction

KW - Vasopressin receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=70350057331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350057331&partnerID=8YFLogxK

U2 - 10.1038/ki.2009.267

DO - 10.1038/ki.2009.267

M3 - Article

C2 - 19625993

AN - SCOPUS:70350057331

VL - 76

SP - 960

EP - 967

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 9

ER -